Pharming Group Management

Management Kriterienprüfungen 2/4

Pharming Group's CEO ist Simon de Vries , ernannt in Nov 2008, hat eine Amtszeit von 15.58 Jahren. Die jährliche Gesamtvergütung beträgt $2.81M , bestehend aus 24% Gehalt und 76% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 2.15% der Aktien des Unternehmens, im Wert von €10.99M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.3 Jahre bzw. 3.3 Jahre.

Wichtige Informationen

Simon de Vries

Geschäftsführender

US$2.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	24.0%
Amtszeit als Geschäftsführer	15.8yrs
Eigentum des Geschäftsführers	2.1%
Durchschnittliche Amtszeit des Managements	3.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.5yrs

Jüngste Management Updates

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Simon de Vries im Vergleich zu den Einnahmen von Pharming Group verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$13m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$673k	-US$11m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	US$2m	US$636k	US$14m
Sep 30 2022	n/a	n/a	US$30m
Jun 30 2022	n/a	n/a	US$21m
Mar 31 2022	n/a	n/a	US$11m
Dec 31 2021	US$3m	US$681k	US$16m
Sep 30 2021	n/a	n/a	US$22m
Jun 30 2021	n/a	n/a	US$31m
Mar 31 2021	n/a	n/a	US$37m
Dec 31 2020	US$3m	US$614k	US$38m
Sep 30 2020	n/a	n/a	US$44m
Jun 30 2020	n/a	n/a	US$46m
Mar 31 2020	n/a	n/a	US$42m
Jan 01 2020	n/a	n/a	US$41m
Sep 30 2019	n/a	n/a	US$38m
Jun 30 2019	n/a	n/a	US$34m
Mar 31 2019	n/a	n/a	US$29m
Dec 31 2018	US$2m	US$579k	US$29m
Sep 30 2018	n/a	n/a	-US$29m
Jun 30 2018	n/a	n/a	-US$44m
Mar 31 2018	n/a	n/a	-US$80m
Dec 31 2017	US$2m	US$537k	-US$91m

Vergütung im Vergleich zum Markt: SimonDie Gesamtvergütung ($USD2.81M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Dutch ($USD880.73K).

Entschädigung vs. Einkommen: SimonDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Simon de Vries (65 yo)

15.8yrs

Amtszeit

US$2,809,000

Vergütung

Dr. Sijmen De Vries, also known as Simon, M. D., M. B.A., has been the Chief Executive Officer of Pharming Group N. V. since November 03, 2008 and also serves as its Executive Director since October 13, 20...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Sijmen de Vries	President	15.8yrs	US$2.81m	2.13% $ 11.3m
Jeroen Wakkerman	Chief Financial Officer	3.8yrs	keine Daten	0.064% $ 335.6k
Mireille Sanders	Chief Operations Officer	5.1yrs	keine Daten	0.12% $ 622.4k
Susanne Embleton	Investor Relations Manager	no data	keine Daten	keine Daten
Ruud Van Outersterp	Chief Ethics & Compliance Officer	3.3yrs	keine Daten	0.024% $ 128.7k
Anurag Relan	Chief Medical Officer	3.3yrs	keine Daten	0.027% $ 143.5k
Stephen Toor	Chief Commercial Officer & GM Americas	7.7yrs	keine Daten	0.028% $ 146.2k
Alexander Breidenbach	Chief Business Officer	less than a year	keine Daten	0.0096% $ 50.9k
Bruno M. Giannetti	Consultant	3.3yrs	keine Daten	keine Daten

3.6yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: PHARMDas Führungsteam des Unternehmens gilt als erfahren (3.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Sijmen de Vries	President	15.9yrs	US$2.81m	2.13% $ 11.3m
Leonard Kruimer	Independent Non-Executive Director	3.3yrs	US$90.00k	0.017% $ 87.8k
Mark Pykett	Independent Non-Executive Director	3.8yrs	US$87.00k	0.020% $ 107.2k
Deborah Jorn	Independent Non-Executive Vice-Chairperson	5.3yrs	US$87.00k	0.023% $ 119.3k
Steven Baert	Independent Non-Executive Director	3.3yrs	US$90.00k	0.017% $ 87.8k
Barbara Yanni	Independent Non-Executive Director	3.8yrs	US$94.00k	0.020% $ 107.2k
Richard Peters	Non-Executive Chairman of Board	less than a year	US$46.00k	0.0076% $ 40.2k
Jabine van der Meijs	Independent Non-Executive Director	3.3yrs	US$94.00k	0.017% $ 87.8k

3.5yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: PHARMDie Vorstandsmitglieder gelten als erfahren (3.3 Jahre durchschnittliche Amtszeit).

Pharming Group Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

High number of new directors

High number of new directors

Recent updates

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Insufficient new directors

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 140%

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Price target increased by 8.9% to €1.83

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Now 20% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings: EPS exceeds analyst expectations

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Price target increased to €13.52

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

High number of new directors

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Consensus revenue estimates fall by 14%

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €1.80

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome

Now 21% undervalued after recent price drop